(H(2)en)(2)Cu(8)Sn(3)S(12) contains a trigonal CuS(3)-based framework into which Sn(4+) ions are incorporated, and exhibits multiple channel systems and interesting ion-exchange properties.

Two novel framework compounds, Zn(en) 3Ag2I4 (1) and Ni(en) 3Ag2I4 (2), have been synthesized by a self-assembly reaction. Both of them contain an unexpected framework, Ag2I4(2-) with tridymite topology, and the discrete M(en)3(2+) cations are located in the channels. Their thermal properties and circular dichroism spectra were investigated.

Two copper-rich open-framework sulfides, K(4)Cu(8)Ge(3)S(12) (1) and Rb(4)Cu(8)Ge(3)S(12) (2), have been synthesized under solvothermal conditions. Compounds 1 and 2 are isostructural and contain icosahedral [Cu(8)S(12)](16-) clusters as basic building blocks. These clusters are primitive cubic packed and connect to one another by discrete Ge(4+) ions to generate 3D copper-rich Cu-Ge-S framework and form 3D channels along 100 directions where the alkali metal cations reside. These two open-framework sulfides crystallize in cubic perovskite structure.

This prospective study investigated the efficiency of the tacrolimus (Tac) combined with mycophenolate mofetil (MMF) alone without immunoadsorption (IA) or plasmapheresis (PPH) as treatment for early (within 2 weeks) acute humoral rejection (AHR) in non-sensitized renal allograft recipients. Of 160 patients enrolled in this prospective study, 11 patients had histologically and clinically confirmed early steroid-resistant acute rejection with an antibody response and received Tac-MMF therapy. No other aggressive rescue methods such as IA, PPH were used, according to the study design. Patients (n=11) were followed for 13.8+/-3.5 months; nine were females. The complement-dependent cytotoxicity crossmatch was negative before transplantation in all patients and only positive for panel-reactive antibody in one patient. Most of the rejection episodes were mixed with cellular rejection (four patients met Banff IIA criteria, five patients met Banff IIB, one patient met Banff IB, and one patient met Banff borderline). After 16.19+/-6.16 days of treatment, all rejection episodes were successfully reversed and all graft functions were stable, with a mean serum creatinine level of 1.12+/-0.32 mg/dl during follow-up. No patient suffered from severe infectious complications (except one case of urinary infection). Our investigation suggests that Tac combined with MMF alone is adequate to reverse early mixed cellular and humoral C4d-positive rejection in non-sensitized renal allograft recipients.